From the Founders

Letter from the Chairs

From our 2011 Annual Report.


Dear Friends,

On behalf of the Board of Directors and the Research Consortium, we want to thank all the donors, researchers and academic institutional partners supporting Cure Alzheimer’s Fund research for your help in making 2011 such a successful science year. Guided by leading scientists in the field, Cure Alzheimer’s Fund-supported research continues to make breakthrough progress toward our goal of eradicating Alzheimer’s disease.

Board Update 2010: Our work is fueling progress

Our focus on funding high-quality, innovative work is fueling progress in Alzheimer’s research

Dear Friends,

It has been an outstanding year at Cure Alzheimer’s Fund(CAF). Our strategy of using a business and venture approach for funding research is working. We’ve been recognized in The Wall Street Journal, Time magazine and AARP, featured on NPR and and invited to exclusive conferences at the White House, TEDMED and the Milken Institute.

Update from the Board: December 2009

Dear Friends,

Why should you care about Alzheimer’s research?

Currently, for every dollar spent on Alzheimer’s care, only a penny is spent working toward a cure. This is a bad equation for a disease that is estimated will cost well more than $100 billion in care (Medicare and Medicaid alone) in 2009.


Letter from the Founders - Why You Should Care About Alzheimer's Research

Why should you care about Alzheimer’s research?

Currently, for every dollar spent on Alzheimer's care, only a penny is spent working toward a cure. This is a bad equation for a disease that is estimated to cost more than $100 billion in care (Medicare and Medicaid alone) in 2009.

Cure Alzheimer's Fund Closes 2008 with a Huge Win!

We set out three years ago to jumpstart progress toward a cure for Alzheimer’s disease and we are succeeding.

  • The Alzheimer’s Genome Project™ (AGP), targeting the full set of Alzheimer’s genetic risk factors, identified seventy new genes, a tremendous result and truly breakthrough research.New genes open extensive novel scientific avenues for better understanding the disease and development of effective therapies.
  • Publications announcing these results have begun and findings will continue to be announced in coming months.
  • Other funded work, such as the AlzGene tool which allows researchers around the world to share and analyze information, is driving progress forward in unprecedented ways.

The personal and economic impact of Alzheimer’s is enormous and the path to a cure is through research.

Major Milestone Achieved

When we first met with Dr. Rudy Tanzi to discuss Cure Alzheimer's Fund, we asked him two things:

  1. Can you recruit a group of first-class Alzheimer’s researchers to guide us in our investment in basic research into the causes of the disease?

  2. What is the most important first step we can take to truly make a difference?

Dr. Tanzi answered the first question by assembling the group of researchers known as the Cure Alzheimer’s Fund Research Consortium. They answered the second question thusly: find all the genes that contribute to risk for Alzheimer’s disease.

Dr. Tanzi estimated that task would take about three years and about $3 million. He was right.

Update from the Board - December 2007

Dear Friends:

With the holidays approaching and the conclusion of 3 years of progress at Cure Alzheimer’s Fund, we are grateful for your support and excited about the challenges ahead.

The Progress. We are funding 17 research projects in 8 different outstanding research institutions across the nation. 

Letter from the Co-Founders, Fourth Quarter 2006

Hello Friends,

First, a hearty thank you to all of you who have supported us.  Your money has been put to good use.  The first operating year of Cure Alzheimer’s Fund has been most gratifying for the founders, donors, researchers --- all of us committed to doing what we can to end the scourge of Alzheimer’s disease in our lifetime.

Perspective: A Letter from Henry McCance

Photo of Henry McCance
Henry McCance, Founding Board Member

Henry McCance is a Founding Board member of Cure Alzheimer’s Fund and Chairman of Greylock Partners, a leading venture capital firm with a distinguished and highly successful record of company building. His family situation brought him to this effort as his words describe here.

Venture! From the Chairman of the Board: Jeffrey Morby

To capitalize on this rare “science moment” as Rudy (Tanzi) calls it, we are committed to focused, disciplined funding of targeted research which we refer to as the Venture approach. All of our Founders have strong business backgrounds, and two of us are long-time venture capitalists. We have all made careers from betting on people who rose to excellence and on providing the best resources available to help them achieve their potential. That is the approach we are bringing to Cure Alzheimer’s Fund.